Comment on: "Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews"

G Castellini; E E Nielsen; C Gluud

doi:10.1002/cpt.536

Comment on: "Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews"

Clin Pharmacol Ther. 2017 Jul;102(1):21-24. doi: 10.1002/cpt.536. Epub 2016 Dec 29.

Authors

G Castellini^{1

2

3}, E E Nielsen³, C Gluud³

Affiliations

¹ Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
² Unit of Clinical Epidemiology, I.R.C.C.S. Orthopedic Institute Galeazzi, Milan, Italy.
³ The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark.

PMID: 27727441
DOI: 10.1002/cpt.536

Abstract

Trial Sequential Analysis (TSA) is a frequentist method to help researchers control the risks of random errors in meta-analyses.¹ Fisher et al.² used TSA on cell therapy for heart diseases. The present article discusses the usefulness of TSA and its dependence on the choice of the parameters for calculation of the required information size and the adjacent monitoring boundaries, and comments on the approach by Fisher et al.².

Publication types

Comment

MeSH terms

Cell- and Tissue-Based Therapy*
Heart Diseases*
Humans